Riskpilot← Back to searchSign inGet full accessTargovax Oy
OYIn liquidationY-tunnus 2256588-9Lars Sonckin Kaari 14Research and experimental development on natural sciences and engineering · NACE 7210Est. 2009— employeeswww.targovax.com
Revenue 2023
EUR 36K
-78% vs 2022
EBITDA margin
-11018.5%
+17% vs 2022
Equity ratio
-16938.6%
Financial strength
Net profit 2023
EUR -4,1M
+15% vs 2022
| Revenue | EUR 36K | -78% |
| EBITDA | EUR -4M | +17% |
| Net profit | EUR -4,1M | +15% |
| Total assets | EUR 37K | -99% |
| Equity | EUR -6,3M | -31% |
| Employees | — | — |
Legal name
Targovax Oy
Y-tunnus number
2256588-9
Legal form
Osakeyhtiö
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. maaliskuuta 2009
Share capital
EUR 4 035
Employees
—
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Selvitystilan aikana selvitysmies yksin
Company purpose
Yhtiön toimiala on lääketieteellinen tutkimus ja kehitys sekä lääkeaineiden valmistaminen.
Address
Lars Sonckin Kaari 14
Phone
+358102794000
Email
contact@targovax.com
Website
www.targovax.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 86 | 123 | 173 | 166 | 36 |
| Staff expenses | −523 | −507 | −647 | −481 | −287 |
| EBITDA | −9 133 | −5 784 | −4 410 | −4 804 | −3 972 |
| Depreciation & amort. | −25 | −60 | −6 | −9 | −44 |
| EBIT | −9 158 | −5 844 | −4 416 | −4 813 | −4 015 |
| Net financials | −56 | −131 | −74 | −21 | −100 |
| Profit before tax | −9 213 | −5 975 | −4 490 | −4 834 | −4 116 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −9 213 | −5 975 | −4 490 | −4 834 | −4 116 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 2 624 | 1 827 | 1 448 | 3 003 | 37 |
| Equity | −7 396 | −6 333 | −5 905 | −4 795 | −6 299 |
| Long-term debt | 6 542 | 6 565 | 5 911 | 6 032 | 0 |
| Short-term debt | 3 478 | 1 595 | 1 442 | 1 766 | 6 336 |
| Total debt | 10 021 | 8 160 | 7 353 | 7 798 | 6 336 |
EBITDA margin
-11018.5%
This company
15.8%
Market median
-69837% vs market
20192023
Equity ratio
-16938.6%
This company
38.2%
Market median
-44442% vs market
20192023
Return on equity
-411553100.0%
This company
18.4%
Market median
-2236701730% vs market
20192023
Net profit margin
-11417.4%
This company
8.1%
Market median
-141056% vs market
20192023
Asset turnover
0.97×
This company
1.12×
Market median
+13% vs market
20192023
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20192023
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LH Liquidator | Liquidator | 2024 |
ED Liquidator | Liquidator | 2024 |
| Former (1) | ||
TM Audit | Audit | 2017 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (3) | ||
| Board of Directors | 2020 – 2024 | |
| Chairperson | 2017 – 2022 | |
| Board of Directors | 2017 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Targovax Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Linda Huser | Liquidator | 0 companies |
| Erik Digman Wiklund | Liquidator | 0 companies |
| Tuukka Miikael Kiuru | Audit | 0 companies |
| Kirsi Johanna Hellström | Board of Directors | 0 companies |
| Øystein Soug | Chairperson | 0 companies |
| Raita Lemmikki Heiskanen | Board of Directors | 0 companies |